

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



QingSong Health Corporation

轻松健康集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2661)

**VOLUNTARY ANNOUNCEMENT
BUSINESS PROGRESS OF THE AI EVIDENCE-BASED MEDICAL
AGENT PRODUCT “QSEVIDENCE”**

This announcement is voluntarily made by QingSong Health Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) to inform the Company’s shareholders and potential investors of the latest progress of the Group’s AI evidence-based medical agent product “QSevidence”.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group’s self-developed AI evidence-based medical agent product “QSevidence” has been officially embedded into the Group’s platform “QSmedical”, which provides professional services to physicians and medical professionals, achieving a product-level integration of the Group’s self-developed medical AI capabilities with its proprietary physician service network. “QSevidence” is an evidence-based medical agent designed around evidence-based methodology. Tailored for real clinical scenarios, it provides physicians with interpretable, verifiable, and traceable medical decision support, elevating AI from a “medical question-answering tool” to an “evidence-based decision assistant”.

According to the Group’s internal statistics as of March 31, 2026, the number of medical professional users on the “QSmedical” platform empowered by “QSevidence” reached 69,615, representing a 46.4% increase from 47,554 as of March 31, 2025. Among them:

- The number of ophthalmology medical professional users reached 3,672, representing a 171.0% increase from 1,355 as of March 31, 2025;

- The number of physicians at or above the level of associate chief physician reached 36,678 (accounting for approximately 52.7% of the total medical professional users on the platform), representing a 42.7% increase from 25,701 as of March 31, 2025.

The Board believes that the embedding of “QSevidence” into “QSmedical” marks the formation of a synergistic framework combining the Group’s self-developed evidence-based medical AI capabilities with its large-scale physician service network, enabling leading evidence-based AI capabilities to directly serve the clinical decision-making and professional development needs of frontline medical professionals. The continuous expansion of the platform’s medical professional user base, particularly the fact that physicians at or above the level of associate chief physician account for more than half, reflects the favorable user structure and professional depth of the Group’s digital services for medical professionals. The Board believes that the above progress has laid a solid foundation for the Group’s continued development in the areas of evidence-based medical assistance, digital services for medical professionals, and AI-driven professional healthcare intelligent services.

Currently, the Company has formed a clear, three-tier progressive AI strategy based on its self-developed AIcare technology stack:

1. Infrastructure Foundation: i-DataCloud, providing AI infrastructure capabilities for all business scenarios;
2. Core Model: Dr.GPT vertical medical large model, supporting the intelligence of the entire ecosystem of healthcare services;
3. Vertical Agent Applications: QSevidence series of evidence-based medical agent products, focusing on evidence-based medical scenarios for professional physicians, extending the Group’s AI capabilities from general healthcare services to serious medical domains.

Leveraging the core technological advantages of the AIcare technology stack, the Group will continue to focus on vertical scenarios in the medical and healthcare field. It will deepen the development and deployment of AI agents in areas such as evidence-based medicine, clinical decision-making, physician services, and public health management. The Group aims to build a full-chain AI service matrix covering both professional and user sides, while steadily advancing the digital and intelligent upgrade of medical and healthcare services, thereby injecting sustained momentum into the Group’s long-term high-quality development.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
QingSong Health Corporation
Yang Yin
Chairlady of the Board,
Executive Director and Chief Executive Officer

Hong Kong, April 26, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Ms. YANG Yin as executive director; (ii) Mr. ZHAO Yuping, Mr. ZHENG Kaihuan and Mr. WU Bin as non-executive directors; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Ms. Ji Wenting as independent non-executive directors.